Central Trust Company’s Takeda Pharmaceutical TAK Stock Holding History

Central Trust Company’s Portfolio TAK Stock Details TAK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.86K	Buy	116 +54	+87%	+$894	﹤0.01%	1432
2026 Q1	$1.15K	Hold	62	–	–	﹤0.01%	1407
2025 Q4	$967	Sell	62 -1	-2%	-$14	﹤0.01%	1381
2025 Q3	$919	Buy	63 +62	+6,200%	+$921	﹤0.01%	1332
2025 Q2	$12	Hold	1	–	–	﹤0.01%	1437
2025 Q1	$11	Buy	+1	New	+$14	﹤0.01%	1439
2024 Q4	–	Sell	-32	Closed	-$456	–	1504
2024 Q3	$456	Buy	+32	New	+$454	﹤0.01%	1366
2020 Q1	–	Sell	-25	Closed	–	–	1210
2019 Q4	$0	Hold	25	–	–	﹤0.01%	1215
2019 Q3	$0	Hold	25	–	–	﹤0.01%	1194
2019 Q2	$0	Sell	25 -352	-93%	-$6.41K	﹤0.01%	1177
2019 Q1	$8K	Buy	+377	New	+$7.59K	﹤0.01%	948

Other funds holding TAK

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

BIP

Brandes Investment Partners La Jolla, California $14.3B AUM 23.11% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Central Trust Company's TAK Position: Q2 2026 in Review

Central Trust Company increased its Takeda Pharmaceutical (TAK) stake by 87% in Q2 2026, buying an estimated $894 and bringing the position to 116 shares worth $1.86K. The position accounts for ﹤0.01% of the portfolio, ranked #1432.

Central Trust Company first reported a position in TAK in Q1 2019 and has held it in 11 quarters since. The position peaked at $8K in Q1 2019. 376 funds tracked by Wall St. Rank hold TAK as of Q2 2026.

Central Trust Company held 116 shares of Takeda Pharmaceutical worth $1.86K as of Q2 2026.
Central Trust Company bought 54 Takeda Pharmaceutical shares in Q2 2026, an estimated $894.
Takeda Pharmaceutical made up ﹤0.01% of Central Trust Company's portfolio in Q2 2026, its #1432 holding.
Central Trust Company first reported a position in Takeda Pharmaceutical in Q1 2019 and has held it in 11 quarters since.
Central Trust Company's Takeda Pharmaceutical position peaked at $8K in Q1 2019.
376 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q2 2026.

Based on Central Trust Company's 13F filing for Q2 2026, filed 31 Jul 2026.